PRFX

Painreform Ltd
NASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$3.42M
P/E Ratio
—
EPS
$-4.09
Beta
1.04
52W High
$7.95
52W Low
$0.85
50-Day MA
$1.02
200-Day MA
$2.27
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—

About Painreform Ltd

PainReform Ltd., a pharmaceutical company specializing in clinical stages, is dedicated to the development of therapies that provide an extended period of post-surgical pain relief in Israel. The company is headquartered in Tel Aviv, Israel.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)31,000
Gross Profit (TTM)-95,000
EBITDA$-4.24M
Operating Margin-18114.00%
Return on Equity-45.30%
Return on Assets-21.90%
Revenue/Share (TTM)$0.03
Book Value$5.22
Price-to-Book0.22
Price-to-Sales (TTM)110.25
EV/Revenue1.888
EV/EBITDA-2.32
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$3.50M
Float$3.04M
% Insiders6.58%
% Institutions6.69%

Historical Volatility

HV 10-Day
81.80%
HV 20-Day
67.06%
HV 30-Day
75.80%
HV 60-Day
83.47%
HV Rank
—

Volatility is currently expanding

Latest News

PRF Technologies' GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization

IEA projects global data center electricity consumption to roughly double to 950 TWh by 2030, with consumption from AI-focused data centers expected to triple Company believes GridFeed's existing AI optimization engine is well suited to helping data center operators make better use of limited power capacity TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd.

GlobeNewsWire9/16/2026Neutral
PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform

New structure designed to enable direct strategic investment, partnerships, and commercial collaborations GridFeed built on validated AI technology and commercial engagements with leading renewable energy companies Platform to be showcased to more than 2,500 energy-market professionals at Energy Trading Week Europe in London   TEL AVIV, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd.

GlobeNewsWire9/9/2026Neutral
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms

Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the Planned Phase 2 Clinical Trial of OcuRing™-K, and DeepSolar's Advance Toward Commercial Launch

GlobeNewsWire7/27/2026Neutral
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026

TEL AVIV, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced that its DeepSolar business unit will participate in Energy Trading Week Europe 2026, taking place September 24–25, 2026, at the Business Design Centre in London.

GlobeNewsWire7/21/2026Neutral
PRF Technologies' DeepSolar Successfully Validates Predict™ AI Platform for Renewable Energy Revenue Optimization Using Real-World European Market Data

Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and Intraday Scenarios as the Solution Advances Toward Planned Commercial Launch

GlobeNewsWire7/8/2026Neutral
PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark

Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential as a long-acting, single-administration post-operative analgesic Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRELEF alongside slower absorption and enhanced local tissue retention, reinforcing PRF-110's potential as a long-acting, single-administration post-operative analgesic

GlobeNewsWire6/25/2026Neutral
PRF Technologies Advances DeepSolar Predict™ Toward Commercial Launch as AI Platform Targets Revenue Optimization Across Renewable Energy Markets

Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market decision-making Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filing to address forecasting accuracy, imbalance exposure, storage optimization and real-time market decision-making

GlobeNewsWire5/28/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRFX and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/28/2026